Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

The activity of the kinase inhibitor Gefitinib on CLL cells and stromal interactions.

FY 2011-12

Summary
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults of the Western World. In the large majority of cases, this is a disease affecting B cells of the immune system. Various combinations of chemotherapeutic drugs exist for treatment of this cancer, however many patients are refractory to treatment or have disease remission. Bone marrow transplant can cure disease, but severe side effects can occur and many patients are not eligible. The proposed research will test drugs not in current clinical use for the treatment of CLL using a current cell system involving CLL cells from clinical patients in culture with stromal cells. Stromal cells are supportive cells in the bone marrow which contribute to a protective microenvironment promoting the growth of CLL cells and inhibiting the action of chemotherapeutic drugs, such as Fludarabine. Therefore, this system should provide a more accurate method of drug testing. Drug candidates include Gefitinib and Dasatinib. Both are tyrosine kinase inhibitors with different targets and FDA-approved for treatment in different cancers, but only Dasatinib suppresses the immune system. The specific aims of the proposed research are to test and compare Gefitinib with Dasatinib in leukemic cell lines and then CLL patient samples in co-culture to determine the drug's mechanism of action and to investigate the drug's role in the microenvironment. It is hypothesized that Gefitinib will inhibit survival signaling in CLL B cells and promote cell death, even in the protective microenvironment. It is also hypothesized that this action will be greater than that of Dasatinib, because previous research has shown that Dasatinib is not effective in the microenvironment. This proposed research will provide specific evidence whether these drugs will be effective targeted therapies for aggressive CLL.
Program
Master's Award: Canada Graduate Scholarships
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
252757
Name
DeLong Rebecca F
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The activity of the kinase inhibitor Gefitinib on CLL cells and stromal interactions.
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Research; Chronic Lymphocytic Leukemia
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults of the Western World. In the large majority of cases, this is a disease affecting B cells of the immune system. Various combinations of chemotherapeutic drugs exist for treatment of this cancer, however many patients are refractory to treatment or have disease remission. Bone marrow transplant can cure disease, but severe side effects can occur and many patients are not eligible. The proposed research will test drugs not in current clinical use for the treatment of CLL using a current cell system involving CLL cells from clinical patients in culture with stromal cells. Stromal cells are supportive cells in the bone marrow which contribute to a protective microenvironment promoting the growth of CLL cells and inhibiting the action of chemotherapeutic drugs, such as Fludarabine. Therefore, this system should provide a more accurate method of drug testing. Drug candidates include Gefitinib and Dasatinib. Both are tyrosine kinase inhibitors with different targets and FDA-approved for treatment in different cancers, but only Dasatinib suppresses the immune system. The specific aims of the proposed research are to test and compare Gefitinib with Dasatinib in leukemic cell lines and then CLL patient samples in co-culture to determine the drug's mechanism of action and to investigate the drug's role in the microenvironment. It is hypothesized that Gefitinib will inhibit survival signaling in CLL B cells and promote cell death, even in the protective microenvironment. It is also hypothesized that this action will be greater than that of Dasatinib, because previous research has shown that Dasatinib is not effective in the microenvironment. This proposed research will provide specific evidence whether these drugs will be effective targeted therapies for aggressive CLL.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
DeLong, Rebecca F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~